(GMRE) Global Medical REIT - Overview
Stock: Healthcare Facilities Leasing, Real Estate Investment
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 9.40% |
| Yield on Cost 5y | 4.19% |
| Yield CAGR 5y | 21.23% |
| Payout Consistency | 95.2% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 28.2% |
| Relative Tail Risk | -5.07% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.08 |
| Alpha | -9.47 |
| Character TTM | |
|---|---|
| Beta | 0.576 |
| Beta Downside | 0.771 |
| Drawdowns 3y | |
|---|---|
| Max DD | 39.20% |
| CAGR/Max DD | -0.10 |
Description: GMRE Global Medical REIT January 21, 2026
Global Medical REIT Inc. (NYSE: GMRE) is an internally managed REIT organized in Maryland that acquires and leases medical office and outpatient facilities to physician groups and health-system operators. Its real-estate assets are held through Global Medical REIT L.P., a Delaware limited partnership, while the Company acts as the sole general partner via its wholly-owned subsidiary, Global Medical REIT GP LLC.
As of September 30 2025, the Company owned 92.14 % of the limited-partner interests in the Operating Partnership; the remaining 7.86 % was held by LTIP-unit participants and third-party partners who contributed properties or services in exchange for partnership units. This ownership structure aligns management incentives with long-term asset performance and limits dilution from external capital.
Key market drivers for GMRE include a historically high occupancy rate of roughly 95 % across its portfolio, an average lease term of 10 years that cushions cash-flow volatility, and a sector-wide cap-rate compression to about 5.5 % driven by the aging U.S. population and the shift toward outpatient care. In 2024 the REIT reported an 8 % year-over-year increase in funds-from-operations (FFO) and maintained a debt-to-equity ratio near 0.7, supporting its current dividend yield of roughly 5.5 %.
For a deeper dive into GMRE’s valuation metrics and comparable peers, check the analysis on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: 2.50m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -3.67 > 1.0 |
| NWC/Revenue: -11.18% < 20% (prev -462.7%; Δ 451.5% < -1%) |
| CFO/TA 0.06 > 3% & CFO 72.5m > Net Income 2.50m |
| Net Debt (721.5m) to EBITDA (83.2m): 8.67 < 3 |
| Current Ratio: 0.53 > 1.5 & < 3 |
| Outstanding Shares: last quarter (13.4m) vs 12m ago 408.9% < -2% |
| Gross Margin: 68.76% > 18% (prev 0.79%; Δ 6797 % > 0.5%) |
| Asset Turnover: 11.76% > 50% (prev 10.98%; Δ 0.79% > 0%) |
| Interest Coverage Ratio: 0.81 > 6 (EBITDA TTM 83.2m / Interest Expense TTM 30.9m) |
Altman Z'' -1.25
| A: -0.01 (Total Current Assets 18.7m - Total Current Liabilities 35.2m) / Total Assets 1.27b |
| B: -0.26 (Retained Earnings -332.6m / Total Assets 1.27b) |
| C: 0.02 (EBIT TTM 24.9m / Avg Total Assets 1.26b) |
| D: -0.42 (Book Value of Equity -325.1m / Total Liabilities 767.4m) |
| Altman-Z'' Score: -1.25 = CCC |
Beneish M -2.97
| DSRI: 0.90 (Receivables 8.31m/8.53m, Revenue 148.0m/136.4m) |
| GMI: 1.15 (GM 68.76% / 79.36%) |
| AQI: 1.00 (AQ_t 0.97 / AQ_t-1 0.97) |
| SGI: 1.09 (Revenue 148.0m / 136.4m) |
| TATA: -0.05 (NI 2.50m - CFO 72.5m) / TA 1.27b) |
| Beneish M-Score: -2.97 (Cap -4..+1) = A |
What is the price of GMRE shares?
Over the past week, the price has changed by +6.05%, over one month by +6.82%, over three months by +15.66% and over the past year by +1.41%.
Is GMRE a buy, sell or hold?
- StrongBuy: 4
- Buy: 1
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the GMRE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 40.9 | 11.5% |
| Analysts Target Price | 40.9 | 11.5% |
| ValueRay Target Price | 41 | 11.8% |
GMRE Fundamental Data Overview February 03, 2026
P/S = 6.4943
P/B = 1.1188
P/EG = -26.28
Revenue TTM = 148.0m USD
EBIT TTM = 24.9m USD
EBITDA TTM = 83.2m USD
Long Term Debt = 709.6m USD (from longTermDebt, last quarter)
Short Term Debt = 280.0k USD (from shortTermDebt, last quarter)
Debt = 728.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 721.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.66b USD (940.6m + Debt 728.7m - CCE 7.12m)
Interest Coverage Ratio = 0.81 (Ebit TTM 24.9m / Interest Expense TTM 30.9m)
EV/FCF = 89.21x (Enterprise Value 1.66b / FCF TTM 18.6m)
FCF Yield = 1.12% (FCF TTM 18.6m / Enterprise Value 1.66b)
FCF Margin = 12.59% (FCF TTM 18.6m / Revenue TTM 148.0m)
Net Margin = 1.69% (Net Income TTM 2.50m / Revenue TTM 148.0m)
Gross Margin = 68.76% ((Revenue TTM 148.0m - Cost of Revenue TTM 46.2m) / Revenue TTM)
Gross Margin QoQ = 42.72% (prev 78.31%)
Tobins Q-Ratio = 1.31 (Enterprise Value 1.66b / Total Assets 1.27b)
Interest Expense / Debt = 1.12% (Interest Expense 8.18m / Debt 728.7m)
Taxrate = 12.12% (811.0k / 6.69m)
NOPAT = 21.9m (EBIT 24.9m * (1 - 12.12%))
Current Ratio = 0.53 (Total Current Assets 18.7m / Total Current Liabilities 35.2m)
Debt / Equity = 1.50 (Debt 728.7m / totalStockholderEquity, last quarter 485.3m)
Debt / EBITDA = 8.67 (Net Debt 721.5m / EBITDA 83.2m)
Debt / FCF = 38.73 (Net Debt 721.5m / FCF TTM 18.6m)
Total Stockholder Equity = 510.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.20% (Net Income 2.50m / Total Assets 1.27b)
RoE = 0.49% (Net Income TTM 2.50m / Total Stockholder Equity 510.0m)
RoCE = 2.05% (EBIT 24.9m / Capital Employed (Equity 510.0m + L.T.Debt 709.6m))
RoIC = 1.96% (NOPAT 21.9m / Invested Capital 1.12b)
WACC = 4.96% (E(940.6m)/V(1.67b) * Re(8.04%) + D(728.7m)/V(1.67b) * Rd(1.12%) * (1-Tc(0.12)))
Discount Rate = 8.04% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 125.9%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈36.7m ; Y1≈24.1m ; Y5≈11.0m
Fair Price DCF = N/A (negative equity: EV 350.3m - Net Debt 721.5m = -371.2m; debt exceeds intrinsic value)
EPS Correlation: -48.55 | EPS CAGR: -18.74% | SUE: -0.07 | # QB: 0
Revenue Correlation: 61.29 | Revenue CAGR: 8.05% | SUE: 1.64 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.12 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=0.12 | Chg30d=-2.115 | Revisions Net=+0 | Growth EPS=-46.1% | Growth Revenue=+3.2%